Literature DB >> 6732040

Shortest possible acceptable effective chemotherapy in ambulatory patients with pulmonary tuberculosis. Part II. Results during the 24 months after the end of chemotherapy.

M L Mehrotra, K D Gautam, C K Chaube.   

Abstract

Efficacy of two 4.5-month regimens (3 RSZH / S2H2Z2 and 3 RSZH /RH) and one 3-month regimen (3 RSZH ) in the management of pulmonary tuberculosis is reported (see table 1 for definition of regimen abbreviations). Even when the patients were ambulatory and outpatient attendance was required for supervised drug administration, drug compliance was high (87%). Bacillary sterilization was achieved in 99% of the patients at 3 months. During first year follow-up after cessation of chemotherapy, 6% of the patients receiving the 3 RSZH regimen, 7% of the patients receiving the 3 RSZH / S2H2Z2 regimen, and 2% of the patients receiving the 3 RSZH / R2H2 regimen experienced relapse. During second year follow-up, relapse was observed in only 1 patient receiving the 3 RSZH / S2H2Z2 regimen. The patients who relapsed usually had drug-susceptible strains at the time of relapse. Regression of pulmonary lesions continued even after the cessation of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6732040     DOI: 10.1164/arrd.1984.129.6.1016

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  3 in total

1.  Short course chemotherapy for tuberculosis in children.

Authors:  B L Varudkar
Journal:  Indian J Pediatr       Date:  1985 Nov-Dec       Impact factor: 1.967

Review 2.  Current and potential treatment of tuberculosis.

Authors:  S Houston; A Fanning
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

3.  Drug tolerance in Mycobacterium tuberculosis.

Authors:  R S Wallis; S Patil; S H Cheon; K Edmonds; M Phillips; M D Perkins; M Joloba; A Namale; J L Johnson; L Teixeira; R Dietze; S Siddiqi; R D Mugerwa; K Eisenach; J J Ellner
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.